ES2519690T3 - Método de tratamiento de envenenamiento por organosfósforo - Google Patents
Método de tratamiento de envenenamiento por organosfósforo Download PDFInfo
- Publication number
- ES2519690T3 ES2519690T3 ES05812994.1T ES05812994T ES2519690T3 ES 2519690 T3 ES2519690 T3 ES 2519690T3 ES 05812994 T ES05812994 T ES 05812994T ES 2519690 T3 ES2519690 T3 ES 2519690T3
- Authority
- ES
- Spain
- Prior art keywords
- poisoning
- treatment
- organosphorus
- galantamine
- exposure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Galantamina y agente antimuscarinico para su uso en la prevencion o el tratamiento de envenenamiento por organofósforo (OP), que comprende administrar una cantidad de galantamina de inhibición del envenenamiento por OP a un mamifero despues de la exposición a un OP y administrar ademas una cantidad eficaz de un agente antimuscarinico despues de la exposición a un OP y antes de o de manera simultanea a la galantamina.
Description
Claims (1)
-
imagen1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61312104P | 2004-09-24 | 2004-09-24 | |
US613121P | 2004-09-24 | ||
PCT/US2005/033789 WO2006036686A2 (en) | 2004-09-24 | 2005-09-23 | Method of treating organophosphorous poisoning |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2519690T3 true ES2519690T3 (es) | 2014-11-07 |
Family
ID=36119406
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES05812994.1T Active ES2519690T3 (es) | 2004-09-24 | 2005-09-23 | Método de tratamiento de envenenamiento por organosfósforo |
ES14002959.6T Active ES2662868T3 (es) | 2004-09-24 | 2005-09-23 | Procedimiento para el tratamiento de una intoxicación por una sustancia organofosforada |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES14002959.6T Active ES2662868T3 (es) | 2004-09-24 | 2005-09-23 | Procedimiento para el tratamiento de una intoxicación por una sustancia organofosforada |
Country Status (10)
Country | Link |
---|---|
US (2) | US7888346B2 (es) |
EP (2) | EP1791904B1 (es) |
JP (2) | JP5710092B2 (es) |
CN (1) | CN101044200A (es) |
AU (1) | AU2005289808B2 (es) |
CA (1) | CA2583439C (es) |
ES (2) | ES2519690T3 (es) |
IL (2) | IL182048A0 (es) |
PL (2) | PL1791904T3 (es) |
WO (1) | WO2006036686A2 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9132135B2 (en) * | 2004-09-24 | 2015-09-15 | University Of Maryland, Baltimore | Method of treating organophosphorous poisoning |
WO2008022365A2 (de) * | 2006-08-24 | 2008-02-28 | Sanochemia Ltd. | Mittel zum beeinflussen der wirkungen von organophosphorverbindungen und verwendung von galanthamin, dessen derivaten und analoga zum herstellen solcher mittel |
US20140120157A1 (en) | 2012-09-19 | 2014-05-01 | Georgetown University | Targeted liposomes |
EP2711000B1 (en) * | 2012-09-19 | 2019-04-03 | Georgetown University | Targeted Liposomes |
CN103041368B (zh) * | 2013-01-18 | 2014-04-02 | 新乡医学院 | 藻蓝蛋白在制备防治有机磷农药所致胚胎毒性的药物中的应用 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4292308A (en) * | 1979-08-21 | 1981-09-29 | Biotherapeutics, Inc. | Treatment of animals exposed to or subject to exposure to organophosphate animal poisonous nerve agents |
US4550113A (en) | 1982-08-19 | 1985-10-29 | Nauchno-Issledovatelsky Institut Po Biologicheskikm Ispytaniyam Khimicheskikh Soedineny | 9-Amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)quinoline monohydrate hydrochloride as stimulant of neuro-muscular transmission of smooth muscles |
RU2057531C1 (ru) | 1986-07-01 | 1996-04-10 | Всероссийский научный центр по безопасности биологически активных веществ | Средство для стимуляции обучения и памяти |
US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
US5480651A (en) | 1992-03-16 | 1996-01-02 | Regents Of The University Of California | Composition and method for treating nicotine craving in smoking cessation |
DE4342173A1 (de) | 1993-12-10 | 1995-06-14 | Lohmann Therapie Syst Lts | Pharmazeutische Formulierung zur Prophylaxe bzw. Vorbehandlung einer Vergiftung durch phosphororganische Cholinesterasehemmer |
DE4342174C1 (de) * | 1993-12-10 | 1995-05-11 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System sowie ein Verfahren zur Herstellung eines transdermalen therapeutischen Systems zur kombinierten transdermalen Anwendung von Physostigmin und Scopolamin für die Prophylaxe und zur Vorbehandlung einer Vergiftung durch hochtoxische phosphororganische Nervengifte, insbesondere Soman und seine Verwendung |
GB9606736D0 (en) | 1996-02-19 | 1996-06-05 | Shire International Licensing | Therapeutic method |
US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
US6576636B2 (en) | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
TW506836B (en) * | 1996-06-14 | 2002-10-21 | Janssen Pharmaceutica Nv | Fast-dissolving galanthamine hydrobromide tablet |
US6261537B1 (en) | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
US6331289B1 (en) | 1996-10-28 | 2001-12-18 | Nycomed Imaging As | Targeted diagnostic/therapeutic agents having more than one different vectors |
AU733495B2 (en) | 1996-10-28 | 2001-05-17 | Nycomed Imaging As | Improvements in or relating to diagnostic/therapeutic agents |
WO1999013864A2 (en) | 1997-09-19 | 1999-03-25 | Shire Laboratories, Inc. | Solid solution beadlet |
US20030077227A1 (en) | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
UA66370C2 (en) | 1997-12-16 | 2004-05-17 | Lilly Co Eli | Arylpiperazines having activity to setotonin 1 receptors |
US6211230B1 (en) * | 1999-09-27 | 2001-04-03 | The United States Of America As Represented By The Secretary Of The Army | Method of reducing brain damage resulting from seizures |
TW558554B (en) | 1999-10-29 | 2003-10-21 | Takeda Chemical Industries Ltd | Crystals of oxyiminoalkanoic acid derivative |
US6617361B2 (en) | 1999-11-05 | 2003-09-09 | Be Able, Llc | Behavior chemotherapy |
MXPA02005667A (es) | 1999-12-10 | 2004-09-10 | Bonnie Davis | Analogos de galantamina y licoramina como moduladores de los receptores nicotinicos. |
JP2001261652A (ja) | 2000-03-21 | 2001-09-26 | Suntory Ltd | 二置換イミノヘテロサイクリック化合物 |
ES2559273T3 (es) | 2000-05-08 | 2016-02-11 | Janssen Pharmaceutica Nv | Profármacos de pirimidinas que inhiben la replicación del VIH |
US6610713B2 (en) | 2000-05-23 | 2003-08-26 | North Shore - Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
US6756385B2 (en) | 2000-07-31 | 2004-06-29 | Pfizer Inc. | Imidazole derivatives |
PE20020394A1 (es) | 2000-08-18 | 2002-06-21 | Agouron Pharma | Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2 |
IT1317908B1 (it) | 2000-09-15 | 2003-07-15 | S I S S A Scuola Internaz Supe | Muteine del frammento peptidico cgrp 1-7 e loro uso come potenziatoridei recettori nicotinici neuronali. |
US6589504B1 (en) | 2000-09-22 | 2003-07-08 | Pharmacia & Upjohn Company | Compounds and methods for diagnosing and treating amyloid-related conditions |
EP1340749A4 (en) | 2000-11-17 | 2007-09-05 | Takeda Pharmaceutical | isoxazole |
JP4012068B2 (ja) | 2000-12-22 | 2007-11-21 | シェーリング コーポレイション | ムスカリンアンタゴニスト |
DE60221098T2 (de) | 2001-02-02 | 2008-01-24 | Takeda Pharmaceutical Co. Ltd. | Kondensierte heterocyclische derivate |
JP2004529117A (ja) | 2001-02-08 | 2004-09-24 | シェーリング コーポレイション | 認知欠陥障害の処置における二重のh3/m2アンタゴニストの使用 |
ATE315555T1 (de) | 2001-05-11 | 2006-02-15 | Pfizer Prod Inc | Thiazolderivate und ihre verwendung als cdk- inhibitoren |
KR100437972B1 (ko) | 2001-10-27 | 2004-07-02 | 한국과학기술연구원 | 피롤리디논 유도체, 이의 제조 방법 및 이를 포함하는제약 조성물 |
KR100432283B1 (ko) | 2001-10-27 | 2004-05-22 | 한국과학기술연구원 | 무스카린성 아세틸콜린 수용체에 작용하는테트라하이드로피리딘 유도체 |
WO2003039467A2 (en) | 2001-11-02 | 2003-05-15 | Diagenics International Corporation | Monoclonal antibodies specific for beta-amyloid. |
GB0202900D0 (en) | 2002-02-07 | 2002-03-27 | Laxdale Ltd | Novel formulations of drugs |
US7015345B2 (en) | 2002-02-21 | 2006-03-21 | Asahi Kasei Pharma Corporation | Propionic acid derivatives |
AU2003228796A1 (en) * | 2002-05-01 | 2003-11-17 | Eisai Co., Ltd. | Cholinesterase inhibitors to prevent injuries caused by chemicals |
CN1389462A (zh) | 2002-07-12 | 2003-01-08 | 复旦大学 | 大叶蒟素及其同系物,和在制备药物组合物中的应用 |
US7045527B2 (en) | 2002-09-24 | 2006-05-16 | Amgen Inc. | Piperidine derivatives |
US20040067934A1 (en) * | 2002-10-03 | 2004-04-08 | Parys Wim Louis Julien | Use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
MXPA05004381A (es) | 2002-10-25 | 2006-02-10 | Collegium Pharmaceutical Inc | Estereoisomeros de para-hidroxi-milnacipran y metodos de uso de los mismos. |
US20050013869A1 (en) | 2003-07-18 | 2005-01-20 | Chaw Cheng Shu | Sustained release formulation for carbamates and a method therefor |
-
2005
- 2005-09-23 ES ES05812994.1T patent/ES2519690T3/es active Active
- 2005-09-23 PL PL05812994T patent/PL1791904T3/pl unknown
- 2005-09-23 PL PL14002959T patent/PL2813225T3/pl unknown
- 2005-09-23 WO PCT/US2005/033789 patent/WO2006036686A2/en active Application Filing
- 2005-09-23 CA CA2583439A patent/CA2583439C/en not_active Expired - Fee Related
- 2005-09-23 ES ES14002959.6T patent/ES2662868T3/es active Active
- 2005-09-23 AU AU2005289808A patent/AU2005289808B2/en not_active Ceased
- 2005-09-23 EP EP05812994.1A patent/EP1791904B1/en active Active
- 2005-09-23 CN CNA2005800360631A patent/CN101044200A/zh active Pending
- 2005-09-23 JP JP2007533601A patent/JP5710092B2/ja not_active Expired - Fee Related
- 2005-09-23 US US11/575,945 patent/US7888346B2/en not_active Expired - Fee Related
- 2005-09-23 EP EP14002959.6A patent/EP2813225B1/en active Active
-
2007
- 2007-03-20 IL IL182048A patent/IL182048A0/en not_active IP Right Cessation
-
2011
- 2011-02-14 US US13/027,129 patent/US8703762B2/en not_active Expired - Fee Related
-
2012
- 2012-02-22 IL IL218241A patent/IL218241A/en not_active IP Right Cessation
-
2013
- 2013-04-24 JP JP2013091045A patent/JP2013173773A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20080070900A1 (en) | 2008-03-20 |
WO2006036686A2 (en) | 2006-04-06 |
EP1791904B1 (en) | 2014-08-27 |
AU2005289808A2 (en) | 2008-07-31 |
JP5710092B2 (ja) | 2015-04-30 |
US8703762B2 (en) | 2014-04-22 |
CA2583439A1 (en) | 2006-04-06 |
PL1791904T3 (pl) | 2015-02-27 |
EP1791904A2 (en) | 2007-06-06 |
WO2006036686A3 (en) | 2007-02-22 |
US20110144093A1 (en) | 2011-06-16 |
JP2013173773A (ja) | 2013-09-05 |
AU2005289808B2 (en) | 2011-11-03 |
ES2662868T3 (es) | 2018-04-10 |
EP2813225A1 (en) | 2014-12-17 |
EP2813225B1 (en) | 2017-12-13 |
IL182048A0 (en) | 2007-07-24 |
IL218241A0 (en) | 2012-04-30 |
PL2813225T3 (pl) | 2018-11-30 |
CA2583439C (en) | 2016-05-10 |
AU2005289808A1 (en) | 2006-04-06 |
EP1791904A4 (en) | 2009-01-21 |
JP2008514609A (ja) | 2008-05-08 |
CN101044200A (zh) | 2007-09-26 |
US7888346B2 (en) | 2011-02-15 |
IL218241A (en) | 2016-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2487496T3 (es) | Agente para aliviar el síndrome metabólico | |
ES2505643T3 (es) | Galectina para uso en el tratamiento del síndrome del ojo seco | |
ES2581331T3 (es) | Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática | |
AR047841A1 (es) | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios | |
ES2483725T3 (es) | Composición básica cosmética y su uso | |
ES2524320T3 (es) | Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo | |
AR054094A1 (es) | Tratamientos de cancer | |
CL2010000188A1 (es) | Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso. | |
ES2524458T3 (es) | DNasa para el tratamiento de la subfertilidad masculina | |
ES2529147T3 (es) | Método para usar los inhibidores de la histona deacetilasa y monitorear biomarcadores en la terapia de combinación | |
AR109605A2 (es) | Método para tratar enfermedades vasculares periféricas, composición y utilización | |
ES2502472T3 (es) | Composición adhesiva para su uso en un inmunosensor | |
ES2575152T3 (es) | Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores | |
CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
ES2519690T3 (es) | Método de tratamiento de envenenamiento por organosfósforo | |
AR043258A1 (es) | Formulacion, complejo antiacido omeprazol - liberacion inmediata, para supresion rapida y sostenida de la acidez gastrica | |
CR8766A (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
CL2007002331A1 (es) | Composicion oral solida que comprede uno o mas farmacos antirretrovirales y al menos un polimero insoluble en agua, en relacion aproximadamente 1:1 hasta 1:6; proceso de elaboracion; y uso para el tratamiento del vih. | |
ECSP099239A (es) | Determinadas amidas sustituidas, método de elaboración y método de uso de las mismas | |
BRPI0718523B8 (pt) | Forma de dosagem, e, método para preparar a forma de dosagem | |
ES2526913T3 (es) | Composición farmacéutica que contiene neurotoxina 2 botulínica | |
CO2022013777A2 (es) | Uso de agentes para el tratamiento de condiciones respiratorias | |
ECSP088793A (es) | Combinación Farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamo | |
CL2008001782A1 (es) | Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion. | |
ECSP11010762A (es) | Composición tópica para el tratamiento de queratosis actínica |